tradingkey.logo

Cannabis company Cronos Q2 revenue up 21% but misses estimates

ReutersAug 7, 2025 11:44 AM


Overview

  • Cronos Q2 2025 net revenue grows 21% yr/yr, misses analyst expectations

  • Gross profit rises significantly due to higher sales prices and efficiencies

  • Co reports net loss of $38.5 mln, impacted by foreign exchange losses


Outlook

  • Cronos expects accelerated growth in H2 2025

  • Company anticipates sales boost from Cronos GrowCo expansion in Fall 2025

  • Company sees positive impact from anti-dumping duty veto in Israel


Result Drivers

  • INTERNATIONAL DEMAND - Record international and Israel revenue driven by strong global demand for cannabis products

  • CRONOS GROWCO CONTRIBUTION - Consolidation of Cronos GrowCo added $2.2 mln to Q2 2025 net revenue

  • ISRAEL MARKET - Record revenue and sales volume in Israel driven by strong demand for high-quality medical cannabis and effective operations, per CEO Mike Gorenstein


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Miss

$2.21 mln

$32.90 mln (1 Analyst)

Q2 Net Income

-$38.48 mln

Q2 Adjusted EBITDA

$1.69 mln

Q2 Gross Margin

43.0%

Q2 Capex

$3.84 mln

Q2 Gross Profit

$14.50 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

Press Release: ID:nGNX880CYb

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI